The impact of gastroesophageal reflux disease on health-related quality of life

American Journal of Medicine

Volumn 104, Issue 3, 1998, Pages 252-258

  Revicki, Dennis A ^a,b   Wood, Martha ^b   Maton, Paul N ^c   Sorensen, Sonja ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATTAPULGITE; RANITIDINE;

ADULT; ARTICLE; DYSPHAGIA; EMOTION; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SOCIAL STATUS; TREATMENT OUTCOME;

ADULT; ANTI-ULCER AGENTS; DEPRESSION; DIABETES MELLITUS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; QUALITY OF LIFE; RANITIDINE; SEVERITY OF ILLNESS INDEX;

EID: 0032033112     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00354-9     Document Type: Article

References (28)

1. 1. Guyatt Gh, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118:622-629.
2. 2. Revicki DA. Health care technology assessment and health-related quality of life. In: D Banta, B Luce, eds. Health Care Technology and Its Assessment: An International Perspective. New York: Oxford University Press; 1993:114-131.
3. 3. Wiklund I. Aspects of quality of life in gastrointestinal disease: some methodological issues. Scand J Gastroenterol. 1995;30(suppl 208): 129-132.
4. 4. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes. JAMA. 1995;273:59-65.
5. 5. Wenger NK, Mattson ME, Furberg CD, Elinson J. Assessment of quality of life in clinical trials of cardiovascular therapies. Am J Cardiol. 1984;54:908-912.
6. 6. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis. 1976;21: 953-956.
7. 7. Hewson EG, Sinclair JW, Dalton CB, Richter JE. Twenty-four hour esophageal pH monitoring: the most useful test for evaluating noncardic chest pain. Am J Med. 1991;90:576-583.
8. 8. Wiener GJ, Koufman JA, Wu WC, et al. Chronic hoarseness secondary to gastroesophageal reflux disease: documentation with 24-hour ambulatory pH monitoring. Am J Gastroenterol. 1989;84: 1503-1508.
9. 9. Sontag SJ, O'Connell S, Khandelwal S, et al. Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy. Gastroenterology. 1990;99:613-690.
10. 10. DeVault KR, Castell DO. Current diagnosis and treatment of gastroesophageal reflux disease. Mayo Clin Proc. 1994;69:867-876.
11. 11. Fennerty MB, Castell D, Fendrick AM, et al. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment. Arch Intern Med. 1996;156:477-482.
12. 12. Hixson LJ, Kelley CL, Jones WN, Tuohy CD. Current trends in pharmacotherapy for gastroesophageal reflux disease. Arch Intern Med. 1992;152:717-723.
13. 13. Kahrilas PJ. Gastroesophageal reflux disease. JAMA. 1996;276:983-988.
14. 14. Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol. 1993;28: 18-21.
15. 15. Dimenas E, Glise H, Hallerback B, et al. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol. 1995;30:1046-1052.
16. 16. Chal KL, Stacey JH, Sacks GE. The effect of ranitidine on symptom relief and quality of life of patients with gastro-esophageal reflux disease. Br J Clin Pract. 1995;49:73-77.
17. 17. Rush DR, Stelmach WJ, Young TL, et al. Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study. J Fam Pract. 1995;41:126-136.
18. 18. Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston, Massachusetts: The Health Institute, New England Medical Center, 1993.
19. 19. Ware JE Jr, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, Massachusetts: The Health Institute, New England Medical Center, 1994.
20. 20. Ware JE Jr, Kosinski M, Bayliss AS, et al. Comparison of methods of scoring and statistical analysis of the SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care. 1995;33:AS264-AS279.
21. 21. Tarlov AR, Ware JE, Greenfield S, et al. The Medical Outcomes Study: an application of methods for monitoring the results of medical care. JAMA. 1989;262:925-930.
22. 22. Vickery BG, Hays RD, Rausch R, et al. Quality of life of epilepsy surgery patients as compared with outpatients with hypertension, diabetes, heart disease, and/or depressive symptoms. Epilepsia. 1994;35:597-604.
23. 23. Dimenas E, Glise H, Hallerback B, et al. Quality of life in patients with upper gastrointestinal symptoms: an improved evaluation of treatment regimens? Scand J Gastroenterol. 1993;28:681-687.
24. 24. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: results from the Medical Outcomes Study. JAMA. 1989;262:907-913.
25. 25. Simon GE, Revicki DA, Grothaus MA, VonKorff M. SF-36 summary scores: are physical and mental health truly distinct? Med Care. In press.
26. 26. Watson RGP, McDougall NI, Tham TCK, Johnston BT. The effect of omeprazole on quality of life in patients with the "sensitive oesophagus": a double blind cross-over placebo controlled study. Gut. 1995;37(suppl 2):A45.
27. 27. Marquis P, Sapede C, Bechade D, et al. Development and psychometric validation of a disease-specific quality of life questionnaire in gastro-esophageal reflux. Qual Life Res. 1995;4:457-458.
28. 28. Young TL, Kirchdoerfer LJ, Osterhaus JT. A development and validation process for a disease-specific quality of life instrument. Drug Infor J. 1996;30:185-1.